Cargando…

Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells

Cholangiocarcinoma (CCA) is a dismal cancer. At present, there is no effective chemotherapeutic regimen for CCA. This may be due to the marked resistance of CCA to chemotherapy drugs, for which a mechanism remains unknown. Nuclear factor-κB (NF-κB) is constitutively activated in a variety of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Seubwai, Wunchana, Vaeteewoottacharn, Kulthida, Kraiklang, Ratthaphol, Umezawa, Kazuo, Okada, Seiji, Wongkham, Sopit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842550/
https://www.ncbi.nlm.nih.gov/pubmed/26802647
http://dx.doi.org/10.3727/096504015X14424348426071
_version_ 1783644006044925952
author Seubwai, Wunchana
Vaeteewoottacharn, Kulthida
Kraiklang, Ratthaphol
Umezawa, Kazuo
Okada, Seiji
Wongkham, Sopit
author_facet Seubwai, Wunchana
Vaeteewoottacharn, Kulthida
Kraiklang, Ratthaphol
Umezawa, Kazuo
Okada, Seiji
Wongkham, Sopit
author_sort Seubwai, Wunchana
collection PubMed
description Cholangiocarcinoma (CCA) is a dismal cancer. At present, there is no effective chemotherapeutic regimen for CCA. This may be due to the marked resistance of CCA to chemotherapy drugs, for which a mechanism remains unknown. Nuclear factor-κB (NF-κB) is constitutively activated in a variety of cancer cells, including CCA. It has been shown to play roles in growth, metastasis, and chemoresistance of cancer. In the present study, we examined whether NF-κB is involved in the chemoresistance of CCA and whether dehydroxymethylepoxyquinomicin (DHMEQ), an effective NF-κB inhibitor, can overcome the drug resistance of CCA. Two CCA cell lines, KKU-M213 and KKU-M214, were treated with DHMEQ and/or chemotherapeutic drugs. Cell viability, apoptosis, and the expressions of the ATP-binding cassette (ABC) transporters were compared. The combination of chemotherapy drugs, 5-fluorouracil, cisplatin, and doxorubicin, with DHMEQ significantly enhanced the cytotoxicity of all chemotherapeutic drugs compared to DHMEQ or drug alone. Furthermore, the mRNA level of ABCB1, a multidrug-resistant protein, was significantly decreased in the 5-fluorouracil combined with DHMEQ-treated cells. These findings suggest that the inhibition of NF-κB by DHMEQ enhanced the chemoresponsiveness of CCA cells, possibly by reducing the expression of ABC transporter. Inhibition of NF-κB may be a potential chemodrug-sensitizing strategy for chemoresistant cancer such as CCA.
format Online
Article
Text
id pubmed-7842550
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cognizant Communication Corporation
record_format MEDLINE/PubMed
spelling pubmed-78425502021-02-16 Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells Seubwai, Wunchana Vaeteewoottacharn, Kulthida Kraiklang, Ratthaphol Umezawa, Kazuo Okada, Seiji Wongkham, Sopit Oncol Res Article Cholangiocarcinoma (CCA) is a dismal cancer. At present, there is no effective chemotherapeutic regimen for CCA. This may be due to the marked resistance of CCA to chemotherapy drugs, for which a mechanism remains unknown. Nuclear factor-κB (NF-κB) is constitutively activated in a variety of cancer cells, including CCA. It has been shown to play roles in growth, metastasis, and chemoresistance of cancer. In the present study, we examined whether NF-κB is involved in the chemoresistance of CCA and whether dehydroxymethylepoxyquinomicin (DHMEQ), an effective NF-κB inhibitor, can overcome the drug resistance of CCA. Two CCA cell lines, KKU-M213 and KKU-M214, were treated with DHMEQ and/or chemotherapeutic drugs. Cell viability, apoptosis, and the expressions of the ATP-binding cassette (ABC) transporters were compared. The combination of chemotherapy drugs, 5-fluorouracil, cisplatin, and doxorubicin, with DHMEQ significantly enhanced the cytotoxicity of all chemotherapeutic drugs compared to DHMEQ or drug alone. Furthermore, the mRNA level of ABCB1, a multidrug-resistant protein, was significantly decreased in the 5-fluorouracil combined with DHMEQ-treated cells. These findings suggest that the inhibition of NF-κB by DHMEQ enhanced the chemoresponsiveness of CCA cells, possibly by reducing the expression of ABC transporter. Inhibition of NF-κB may be a potential chemodrug-sensitizing strategy for chemoresistant cancer such as CCA. Cognizant Communication Corporation 2016-01-21 /pmc/articles/PMC7842550/ /pubmed/26802647 http://dx.doi.org/10.3727/096504015X14424348426071 Text en Copyright © 2016 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.
spellingShingle Article
Seubwai, Wunchana
Vaeteewoottacharn, Kulthida
Kraiklang, Ratthaphol
Umezawa, Kazuo
Okada, Seiji
Wongkham, Sopit
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title_full Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title_fullStr Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title_full_unstemmed Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title_short Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
title_sort inhibition of nf-κb activity enhances sensitivity to anticancer drugs in cholangiocarcinoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842550/
https://www.ncbi.nlm.nih.gov/pubmed/26802647
http://dx.doi.org/10.3727/096504015X14424348426071
work_keys_str_mv AT seubwaiwunchana inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells
AT vaeteewoottacharnkulthida inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells
AT kraiklangratthaphol inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells
AT umezawakazuo inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells
AT okadaseiji inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells
AT wongkhamsopit inhibitionofnfkbactivityenhancessensitivitytoanticancerdrugsincholangiocarcinomacells